文献速递前列腺癌

认知融合与软件融合靶向前列腺穿刺诊断临床显著前列腺癌的多中心随机非劣效试验

Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION).
PubMed 文献 · Eur Urol · 2026-07-10

IMAGINATION试验纳入648例以穿刺初治为主、PSA 4-20 ng/ml且PI-RADS≥3的男性,在中国9个中心随机1:1接受认知融合或软件融合靶向穿刺联合系统穿刺。意向治疗分析中,靶向穿刺检出csPCa率分别为32%和34%,调整风险差-1.02个百分点(90%CI -5.6至3.6),证实非劣效;但BMI交互显著(p<0.001),BMI≥24 kg/m2时软件融合检出更优。

要点

  • 认知融合靶向穿刺在预设-10个百分点界值内非劣于软件融合。
  • BMI<24 kg/m2者认知融合检出最佳,BMI≥24 kg/m2者软件融合更优。
  • 两种融合方式不良事件率相当(15% vs 18%)。

核心结论

  • 认知融合靶向穿刺在预设-10个百分点界值内整体非劣于软件融合靶向穿刺。
  • BMI交互显著(p<0.001),肥胖人群认知融合可行性存疑,软件融合严格更优。

研究设计与样本

  • 多中心、随机、盲法、非劣效试验,纳入648例以穿刺初治为主、PSA 4-20 ng/ml、PI-RADS≥3的男性,来自中国9个中心。
  • 1:1随机分配至认知融合或软件融合靶向穿刺,随后行系统穿刺。

主要发现

  • 意向治疗人群(认知融合327例、软件融合321例)中,靶向穿刺检出csPCa率分别为32%和34%。
  • 调整风险差-1.02个百分点(90%CI -5.6至3.6),满足非劣效。
  • 靶向联合系统穿刺检出csPCa率分别为35-39%,差异-1.50%(90%CI -6.4至3.4)。
  • BMI交互显著(p<0.001):BMI<24 kg/m2者认知融合检出最佳,BMI≥24 kg/m2者软件融合检出更优。
  • 不良事件率相当(15% vs 18%)。

关键数值与推荐

  • 主要终点为靶向穿刺检出csPCa(ISUP分级组≥2)。
  • 预设非劣效界值为-10个百分点,采用广义估计方程评估。

临床怎么用

  • 认知融合可作为软件融合的可及性替代方案,但需结合BMI选择术式。
  • BMI≥24 kg/m2患者优先考虑软件融合靶向穿刺以优化csPCa检出。

局限性

  • 试验主要在亚洲人群中进行,特定BMI切点的地理外推需谨慎。
  • 未来需在亚洲和西方人群中以前瞻性试验将BMI效应作为主要终点评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Magnetic resonance imaging-targeted prostate biopsy relies heavily on costly software-fusion platforms, limiting global accessibility. OBJECTIVE: We aimed to determine whether cognitive fusion (mental registration) is noninferior to software-based fusion targeted biopsy for detecting clinically significant prostate cancer (csPCa). DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized, blinded, noninferiority trial enrolled 648 predominantly biopsy-naive men (prostate-specific antigen 4-20 ng/ml; Prostate Imaging Reporting and Data System ≥3) at nine centers in China. INTERVENTION: Participants were randomly assigned 1:1 to cognitive fusion or software-based fusion targeted biopsy, followed by systematic biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was csPCa (ISUP grade group ≥2) detection on targeted biopsy, evaluated using generalized estimating equations with a prespecified -10 percentage point noninferiority margin. RESULTS AND LIMITATIONS: In the intention-to-treat population (327 cognitive and 321 software), targeted biopsy detected csPCa in 32% and 34% of the patients, respectively. The adjusted risk difference was -1.02 percentage points (90% confidence interval [CI], -5.6 to 3.6), establishing noninferiority. Combined targeted and systematic biopsy detected csPCa in 35-39% of the patients, respectively (difference, -1.50% [90% CI, -6.4 to 3.4]). A significant body mass index (BMI) interaction was observed (p < 0.001): cognitive fusion performed best in men with BMI <24 kg/m2, whereas software-based fusion improved detection in men with BMI ≥24 kg/m2. Adverse event rates were comparable (15% vs 18%). Limitations include conducting the trial predominantly in Asian populations, necessitating cautious geographic extrapolation of specific BMI cutoffs. CONCLUSIONS: Cognitive fusion is diagnostically noninferior to software-based fusion within a prespecified -10% margin overall. However, a significant BMI interaction raises serious concerns regarding the diagnostic feasibility of cognitive fusion in obese populations, where software-based fusion is strictly superior. Future prospective trials in both Asian and Western populations must evaluate the BMI effect as a primary end point. TRIAL REGISTRATION: ClinicalTrials.gov NCT04271527.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. He BM, Zhang K, Zhou Z, et al. Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol. 2026. PMID: 42431755. doi:10.1016/j.eururo.2026.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。